Nordicus Partners Corp (NORD) · Nov 4, 2026 · Share issuance
$80K private placement — 40,000 shares at $2.00; $80,000 proceeds
Nordicus Partners’ share issuance brings in $80,000 of private capital. The cash helps a pre-revenue biotech, but the amount is too small to reset its financing needs.
Nordicus is a pre-revenue biotech accelerator funding a portfolio of early-stage Nordic drug programs. Its lead assets remain preclinical, with Orocidin and Bio-Convert targeting oral diseases and NoviThera developing a psoriasis treatment; the company is aiming for clinical progress rather than near-term product revenue.
The financing is helpful but too small to change that underlying story. Nordicus closed a private offering of 40,000 restricted shares at $2.00 each for $80,000 in proceeds. 〔0〕 The cash matters because the latest reported quarter showed only $5,784 of cash and $159,844 of operating cash use, while management disclosed substantial doubt about continuing as a going concern.
| October 29, 2026 | Comparison | |
|---|---|---|
| Shares issued (Private offering) | 40,000 | 19,443,896 outstanding |
| Price per share (Private offering) | $2.00 | — |
| Proceeds (Private offering) | $80,000 | — |
Dilution is limited, but the capital runway extension is also limited. The new shares represent roughly 0.2% of the latest reported shares outstanding, so this is not a meaningful ownership reset; however, $80,000 covers only about half of the company’s most recently reported quarterly operating cash burn. The filing therefore supports near-term liquidity without resolving the broader need for additional financing. 〔1〕
Bottom line: This is modestly helpful financing for a cash-constrained company, but not a business-changing event. It buys some time while Nordicus works toward its clinical milestones; it does not materially reduce the company’s funding risk or advance the drug programs themselves.
Orocidin Phase IIa trial, first half 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!